This is my part of an oral presentation

As my colleague previously said, type I Diabetes results from a failure of the body to produce enough insulin, resulting in high blood glucose levels.

Therefore, the patient has to regularly inject insulin to survive. They must carefully monitor the dosage and timing of insulin injections in order to keep an optimal glucose regulation. Too little insulin, and their glucose levels rise, leaving them at risk over time for complications such as blindness and kidney failure; too much insulin will result in hypoglycemia, making them vulnerable to coma or, in extreme circumstances, even cause death.

Recently, researchers have been conducting clinical trials for the latest generation of artificial pancreas. Contrary to what the name might suggest, artificial pancreas systems do not involve transfer of tissue. Rather, the term refers to a complex technology that uses computer algorithms to automatically and continuously sense a person's unique blood glucose balance and then substitute the endocrine function of a healthy pancreas. The artificial pancreas has been perceived as revolutionary for diabetic people. Their insulin administration could occur automatically, letting them finally think about something else other than their blood glucose balance.

But as you can see, the artificial pancreas is still quite invasive, the patients constantly need to keep these 2 sensors implanted under their skin and two devices in their pocket.

Here comes DCTI. We are a consortium of patient associations, and biotech start ups working together in order to find a way for diabetic people to live just like you and me.